original RESUMO Objetivo. Descrever as características, os fatores prognósticos e a sobrevida global de pacientes com síndrome de compressão após metástase óssea secundária ao câncer de mama. Método: Foi realizado um estudo de sobrevida em mulheres com câncer de mama e metástase óssea , com diagnóstico de síndrome de compressão medular ou radicular em uma única instituição. As características demográficas (idade, estado civil e escolaridade) e clínicas (estadiamento clínico, tratamento cirúrgico do câncer de mama, sítio da metástase, tipo de compressão e óbito) foram coletadas retrospectivamente dos prontuários médicos. Foi considerado desfecho a ocorrência de óbito e censura, os casos vivos no último seguimento. Foi realizada a Regressão de Cox com nível de significância de 95%. Resultados: Foram incluídos 36 casos. O tempo mediano entre o diagnóstico de câncer de mama e a metástase óssea foi de 17 meses (0-167). O óbito ocorreu em 92% dos casos, com mediana de 22 meses (1-99) após o diagnóstico de metástase óssea e 9 meses (0-47) após o diagnóstico de síndrome de compressão. A única variável associada a com o aumento da sobrevida após compressão medular foi o uso de bifosfonatos após a metástase óssea. Conclusão: A sobrevida global após metástase óssea foi de 22 meses e após a sindrome de compressão de 9 meses. O uso de bifosfonatos aumentou a sobrevida global após a síndrome de compressão medular.
INTRODUCTION
The World Health Organization has estimated that there are more than 1.29 million new cases of breast cancer each year, making it the most common cancer among women. In Brazil, there were approximately 576,580 new cases of cancer in 2014, and of these, 57,120 were breast cancer 1 . Although the trend in breast cancer mortality rates has remained declined in some developed countries, in Brazil, mortality rates still increasing in some states, probably because of socioeconomic inequalities 2 .
Therefore, as a result of therapeutic advances in breast cancer, patients are surviving longer, leading to an increased risk of bone metastasis and skeletal-related events 3 . It is estimated that over 50% of breast cancer patients will develop bone metastases during the course of the disease. Studies on cadavers found that 70% of patients died with evidence of this type of metastasis [4] [5] [6] [7] [8] , and patients who experience disease progression primarily to the bone have a median survival of 24 months 6 .
In breast cancer bone metastasis, the most common event (80-90%) that causes bone destruction is an osteolytic lesion, and the least frequent (10%-20%) is abormal osteoblastic bone formation. These lesions can lead to severe pain, pathological fractures, radicular and/ or spinal cord compression syndrome, and hypercalcemia 3, 6, [8] [9] [10] . Spinal cord compression occurs in about 10% of breast cancer patients and results in serious complications that contribute directly to reducing the survival of these patients and affect their quality of life 6, 11, 12 .
Knowledge of the characteristics of women who develop compression syndrome and the factors associated with clinical progression and survival may contribute to the development of preventative strategies and improved quality of life. To date, no studies have identified this feature in the Brazilian population.
This study aims to describe the characteristics, prognostic factors and overall survival of patients with radicular and/or spinal cord compression syndrome after bone metastasis in breast cancer patients. To meet these goals, we retrospectively collect the variables related to demographic characteristics (age, marital status and education) and clinical information (clinical stage, surgical treatment of breast cancer, site of metastasis, type of compression syndrome and death).
METHOD

Design and patients
A survival study was performed in women with breast cancer and bone metastasis, with diagnosis of radicular and/or spinal compression syndrome at a single institution, between May 2006 and April 2007. We excluded those undergoing cancer treatments outside the institution prior to enrollment and patients with an epidural mass. The patients were followed up until April 2010. The study was approved by the institution's research and ethics committee (CEP INCA Nº016/08).
Procedure
The physiotherapy routine of the institution recommends the evaluation of all patients admitted for clinical treatment and referred by the health team for outpatient care using a validated instrument 13 . Thus, it was possible to retrospectively collect the variables related to demographic characteristics (age, marital status and education) and clinical information (clinical stage, surgical treatment of breast cancer, site of metastasis, type of compression syndrome and death). Outcome was considered the occurrence of death and censures, the cases alive at the last follow-up.
Statistical analysis
To describe the profile of patients with compression syndrome, we performed a descriptive analysis of central and dispersion tendencies for continuous variables and absolute and relative frequencies for dichotomous variables. The Kaplan-Meier method was used to evaluate overall survival, based on a statistically significant confidence interval of 95% and p-value of <0.05. Cox regression (enter method) was used to adjust the effect of clinical stage and age at breast cancer diagnosis in relation to clinical and demographic variables and overall survival. The final model was based on a statistically significant level of 95%.
Post-hoc power analysis was conducted to determine whether sufficient power existed to observe an effect, assuming the effect size in the sample is equal to the effect size in the population (Type II error). The power statistical test was performed, considering the follow--up time required to enroll all patients (accrual time), a original significance level of 95%, the follow-up interval, the total number of patients included and the hazard ratio of the predictive variable.
RESULTS
During the study period, 36 women were found to have compression syndrome. The mean age at diagnosis of breast cancer was 53±13.8 years; 36% of them lived with a partner, and 67% had a low educational level (up to 8 years of study). Breast cancer was diagnosed at clinical stage III in 52% and stage IV in 19% of cases. Surgical treatment was possible in 58% of the patients. Metastasis in the liver (28%), lung (14%) and central nervous system (8.3%) was observed concomitant with the bone implant.
The median time between admission to hospital (to start breast cancer treatment) and bone metastasis was 17 months (0-167), and the median time until compression syndrome was 30 months (0-167). Following the diagnosis of bone metastasis, the median time until compression syndrome was 1 month (0-92).
Before the diagnosis of compression syndrome, there was at least one report of back pain in the medical records in 47% of cases. At the time of diagnosis, there were reports of back pain in the lower limbs in 24% and 29%.
Spinal cord compression syndrome occurred in 58% of the cases, radicular syndrome in 36%, and both (spinal cord and radicular) in 6%. Spinal cord compression occurred more frequently in the dorsal region (72%) and radicular compression in the second (29%) and fifth lumbar vertebra (29%; Table 1 ).
Palliative treatment for compression syndrome after bone metastasis was performed in all patients. The treatment used was chemotherapy in 61.1%, bisphosphonates in 75%, radiotherapy in 100% and hormone therapy in 69.4%. All patients underwent physical therapy, and in 97%, orthesis was adapted to stabilize the spine.
Death occurred in 91.7% of cases. The median overall survival was 45 months after admission (95% CI 25-66), 22 months after bone metastasis (95% CI 20-34), and 9 months after compression syndrome (95% CI 3-14; Figure 1 ). Women with single bone metastasis presented better survival (mean of 22 months) than those with bone and other sites of metastasis (mean 12 months) (p<0.043). Those patients that used bisphosphonates after bone metastasis had a mean of 22 months survival and those without this therapy had 12 months (p<0.043; Table 2 ).
In patients who underwent breast cancer surgery (n=21), the number of lymph nodes removed was associated with worst survival (p<0.020; Table 3 ).
After adjusting for the effect of age and clinical stage, the only variable that was associated with increased survival after compression syndrome was the use of bisphosphonates after bone metastasis (HR=9.28; IC 95% 2.82-30.62; p<0.001).
The post-hoc power analysis demonstrated that with a total of 36 patients included in this study, there was a 98% probability that the study would detect a difference at a significance level of 5%, with a true hazard ratio of 9.00. This was based on the assumption that the accrual period was 36 months, with a follow-up period of 36 months.
DISCUSSION
Breast cancer is an important public health problem 2 . Cancer treatment and other aging-related disease can lead to the development of skeletal events. In young women, the chemotherapy can cause early menopause and decreased bone mineral density. The estrogen-inhibiting can affect bone tissue metabolism. These conditions can adversely affect the quality of life of these patients 14 .
Bone metastasis occurs very frequently in breast cancer patients. Patients with bone metastasis have a high risk of developing skeletal-related events such as vertebral compression syndrome, which can affect the quality of life and overall survival 7 . The incidence of bone metastasis after breast cancer were observed in more than 3% of patients with stages III and IV 4 . The risk factors include node status, histological classification of the tumor, nuclear grading of the tumor, size, estrogen and progesterone receptor status, and clinical stage, among other parameters. In this study, our goal was not to evaluate the risk factors for bone metastasis after breast cancer treatment, but to assess the factors associated with overall survival original in women with compression syndrome after bone metastasis. This study included 36 patients with compression syndrome after bone metastasis, comprising all cases of compression syndrome occurring in a single reference institution for breast cancer treatment, between May 2006 and April 2007. The average age at diagnosis of breast cancer was 53 years, and most were diagnosed at the advanced clinical stage (52% stage III and 19% stage IV). In a population-based cohort study, was reported a median age of 67 years among those who developed bone metastasis and skeletal-related events, with the highest incidence observed among patients with advanced stage tumours 7 .
The median time until compression syndrome after bone metastasis was 1 month (0-92). The largest increase in skeletal-related events after bone metastasis occurs in the first year (1-year cumulative incidence = 38.5%) 7 . Our data probably indicate a late diagnosis of bone metastases in our institution.
Spinal cord compression occurred most frequently (72%) in the dorsal region in this study. Bone metastasis predominantly causes osteolytic lesions characterized by increased bone degradation that can result in pain 7 . We found that 47% of our patients had reported back pain in the medical records before the diagnosis of compression syndrome, and at the time of diagnosis, there were reports of back pain in the lower limbs in 24% and 29%.
In this study, death occurred in 92% of cases, 9 months (95% CI 3-14) after the diagnosis of compression syndrome. A similar result was found in others studies, who reports that the overall survival of patients with compression syndrome was 9 months 15 and 12 months 16 after the development of neurological signs. Significantly, longer survival is associated with a longer interval between diagnosis of the tumor and the development of compression syndrome 12 .
The most frequent treatment for metastatic spinal cord compression is radiotherapy alone, although some studies have suggested that selected patients benefit more from surgery plus radiotherapy [17] [18] [19] . The indication for surgical treatment depends of the clinical status of the patients, prognosis, primary tumor and the characteristics of the spinal compression 20 . In our institution, surgery is not routine treatment for patients with compression syndrome, thus, all patients received radiotherapy, and there was no woman underwent surgery. This may also reflect the unfavorable conditions of our population. The bisphosphonates are important bone desorption inhibitors that diminish the recruitment and activity of osteoclasts and increase their apoptosis 14 . These effects make bisphosphonates a treatment choice in many bone diseases characterized by an increase in osteoclastic desorption, such as Paget's disease, fibrous dysplasia, osteogenesis imperfect, reflex sympathetic dystrophy syndrome, vertebral fracture and osteoporosis 21, 22 . In breast cancer patients, the use of bisphosphonates aim to prevent and/or treat cancer-related bone complications 3, 4, 6 . In our study it was not possible to obtain information of the bone characteristics prior to bone metastasis or compression syndrome. After adjustment for age and clinical stage, we found that the only variable that was associated with increased survival after compression syndrome was the use of bisphosphonates after bone metastasis.
This study aimed to describe the characteristics and survival of a series of women with vertebral com-pression syndrome after bone metastasis in a single institution. We included all cases diagnosed between May 2006 and April 2007 at a single institution in Brazil. Due to the small number of patients enrolled, this study may have limited power to detect a significant difference (Type II error) between the survival rate and the clinical and histopathological variables. However, the use of bisphosphonates for bone metastasis was an important predictor of improved survival, with a power to detect this association of 98%.
Given the lack of information about the subject in the literature, this exploratory study may be useful in clinical practice and in designing future studies with a larger sample of patients.
CONCLUSION
In this study, women were young when diagnosed with clinically advanced breast cancer. The median time between registration in the institution for treatment of breast cancer and bone metastasis was 17 months and the median time to compression syndrome was 30 months. Overall survival was 22 months after the diagnosis of bone metastasis and 9 months after spinal cord or radicular compression syndrome. After adjustment for age and clinical stage, the only variable that was associated with increased survival after compression syndrome was the use of bisphosphonates after bone metastasis.
Studies with larger sample sizes and that, in addition to clinical and demographic characteristics, include molecular variables, must be performed to identify predictors of overall survival after bone metastasis and compression syndrome. http://dx.doi.org/10.1590/S1807-59322011000400010 6-0
